Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
XULTOPHY (insulin degludec and liraglutide) is a prescription medication prescribed to improve glycemic control in people who have type 2 diabetes mellitus.
People with type 2 diabetes mellitus still produce insulin, but their bodies have become resistant, requiring extra insulin. Insulin is the primary hormone that lowers blood sugar to normal levels.
Inject XULTOPHY subcutaneously once daily at the same time each day. XULTOPHY can be given with or without food.
XULTOPHY is dosed based on how much insulin a person normally uses. The possible starting doses are:
The maximum daily dose of XULTOPHY is 50 units insulin degludec and 1.8 mg liraglutide.
XULTOPHY contains two active ingredients: long-acting insulin and a GLP-1 receptor agonist.
Insulin degludec is a long-acting insulin that lasts about 24 hours for most patients.
Liraglutide is a GLP-1 receptor agonist that works by slowing down the gastrointestinal tract and by causing the pancreas to release extra insulin.
Tell your doctor or pharmacist if you are taking any medications that mask the signs of hypoglycemia:
The following drugs can affect the blood sugar of people with type 2 diabetes mellitus:
Since liraglutide slows down the gastrointestinal tract, use caution if you are taking the following medications:
XULTOPHY cannot be used by anyone with a history of Medullary Thyroid Cancer (MTC). It is also contraindicated for people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Rotate injection sites to avoid lipodystrophy.
Do not use XULTOPHY in an insulin pump.
The most common adverse reactions from XULTOPHY may include:
Buy XULTOPHY insulin/GLP-1RA combination online from Canda Pharmacy.
Xultophy [package insert] Plainsboro, NJ: Novo Nordisk; 2019